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Abstract
Due to the diversity and breadth of cancer characteristics, the study and elimination of
cancerous cells is a daunting task. Despite this diversity cancer cell share common characteristics
such as anti‐apoptotic mechanisms and avoidance of immune destruction. The importance of
the immune system in counteracting these diverse characteristics has only recently begun to be
appreciated but involvement of the immune system is quickly becoming an essential component
in the development of novel cancer therapies. The following study aims to elucidate the effect of
SMAC mimetics, a class of targeted therapy drugs, on T cells and their potentially induced
proliferation and activation. As previously reported, SMAC mimetics killed tumor cells and
activated non‐canonical NF‐kB in T cells at clinically relevant doses. Surprisingly, none of the
SMAC mimetics augmented T cell proliferation or effector function. These results question the
assumption that SMAC mimetics are likely to boost anti‐tumor immunity in cancer patients.

Introduction
Characteristics of Cancerous Cells
Cancer is an extraordinarily variable condition within the human population. Able to arise
from any cells within the body, the study of the early development of cancer is a daunting task.
However, a widely accepted characteristic of all cancer cells is mutation within the genome that
allows for continuous proliferation and eventual metastasis to other tissues (Hanahan 2000). To
proliferate, a non‐cancerous, healthy cell needs a variety of signals called growth factors to be
able to undergo cell division, but cancerous cells develop methods of proliferating either without
these necessary signals or producing their own. These strategies employed by a malignant cell
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are expansive but revolve around helping the cell become immortal, proliferate continuously,
and avoid destruction by the body (Fig. 1). Immortality and continued proliferation arise from a
cancer cell’s ability to receive sustained proliferative signaling, resist cell death, deregulation of
cellular metabolism, increased access to vasculature, enabling replicative immortality, evading
growth suppressors, activating metastasis, and finally evading replicative immortality.
Simultaneously the cell must avoid destruction, accomplished by avoiding immune detection and
increasing tumor‐promoting inflammation. The majority, if not all, of these characteristics are
produced by the mutation of the instable genome of a potentially malignant cell (Hanahan 2000,
Hanahan 2022).
To proliferate, cells require extracellular growth signals that then bind to specific
receptors on the cell membrane and intracellularly begin the process of cell growth and division.
An obvious challenge faced by a cancer cell is insufficient growth signals necessary to proliferate
at a malignant rate, thus cancer cells have developed ways of either generating a surplus of
growth signals through an autocrine positive feedback loop or influencing neighboring cells into
secreting above‐average levels of growth signals. Additionally, mutations in proteins involved in
progrowth pathways allow a cancerous cell to intensify the signals it receives (Hanahan 2000).
Another hallmark of cancerous cells is the ability to both ignore anti‐growth signals,
thereby working in conjunction with the above characteristic for unchecked growth, as well as
evade signals to undergo programmed cell death or apoptosis (Hanahan 2000). During the GI
phase of the cell cycle a cell preparing to proliferate will monitor the environment for extrinsic
signals that further push the cell into a proliferative phase. Of these signals, almost all pass
through pathways involving pRb, or retinoblastoma protein (Hanahan 2000). Rb is essential as a
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tumor suppressor gene, therefore mutations to this protein are highly advantageous to cancer
cells. Due to the importance of this protein and the signaling pathways that it is involved in, the
vast majority of cancerous cells mutate this protein to ignore antiproliferative signals, allowing
the cell to enter into a proliferative phase of its cycle in the presence of antigrowth signals.
Apoptotic signals also play a large role in controlling the cell cycle and the elimination of
diseased or mutated cells as well as the upregulation of enzymes involved in cell death due to
age. The ability of a cancer cell to become immortal is essential to the production of malignant
tumors and eventual metastasis, evading apoptotic signals both intrinsically and extrinsically. To
achieve this the cell must be able to divide exponentially more than the average cell, but also
must manipulate the surrounding environment to be able to have the space and the nutrients to
expand and metastasize. Circumvention of death due to age is accomplished largely through the
upregulation of telomerase, an enzyme that adds hexanucleotide repeats onto the end of
telomeres to halt the unraveling process that leads to cell death (Hanahan 2000).
To successfully evade cell death a cancerous cell must be able to bypass extrinsic signals
of apoptosis. Within this extrinsic process, the mechanisms of sensors and effectors are equally
important (Hanahan 2000). Sensors, as their name suggests, monitor the extracellular
environment for pro‐apoptotic signals from molecules that are released to induce apoptosis in
diseased cells and induce intracellular pathways leading to eventual cell death. Intracellular
proteases called caspases make up the large majority of the secondary mechanism of apoptosis
and initiate the process of cell death. Mitochondria in particular are central in the vast majority
of apoptotic pathways. Several apoptotic signals converge within the mitochondria to cause the
release of molecules, such as cytochrome C and secondary mitochondrial activator of caspases
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(SMAC), that activate enzymes downstream in the apoptotic pathway (Hanahan 2000).
Molecules such as these are often the source of mutation in cancerous cells that renders the
molecule non‐functional, or inhibition of these molecules can occur by mutated proteins that
block apoptotic signals intracellularly.
Immortal cancerous cells inhabit a space called the tumor microenvironment, and have
developed mechanisms to enhance angiogenesis, the growth of new blood vessels, through the
activation or inhibition of molecules that control angiogenesis within this microenvironment.
Once a tumor has outgrown the space in which it began, it then mutates the adhesive molecules
that bind it to the extracellular matrix allowing tumor cells to circulate to other tissues to begin
new tumors (Hanahan 2000). While the tumor microenvironment is vitally important to the
growth of tumor cells and the promotion of metastasis, intracellular pathways and mutated
proteins are often the focal point of novel treatments that aim to target specific cancerous cells.
The final hallmark of a cancer cell is the avoidance of immune destruction. Cancer cells
primarily evade detection and suppress immune function through manipulation of the tumor
microenvironment and through modified expression of cell surface proteins that regulate
immune cells. Within the TME, immune cells are recruited and reprogrammed by molecules
within the environment that cause a weaker immune response or proliferation and activation of
cells that regulate the immune response (Hanahan 2022, Gonzalez 2008, Yaguchi 2011).
Immune‐suppressive molecules such as IL‐10 and TGF‐B affect the function of nearby immune
cells and suppress action against the cancer cell, such as cytotoxic killing or the recruitment of
other immune cells to the area (Gonzalez 2008). The TME is essential to suppress the immune
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cells within the direct environment of tumor cells, but to further avoid apoptosis cancerous cells
must modify their chemical appearance to avoid detection.
Cancerous cells downregulate the expression of cell surface markers that signal to
immune cells, particularly CD8+ T cells, that the target cell should be eliminated via induced
apoptosis (Gonzalez 2008, Yaguchi 2011). This is a common feature among several different
tumor types, therefore suggesting that cells are responding to evolutionary pressure to
downregulate these presentation molecules to evade immune detection and survive. However,
as cancer rates are not astronomically high within human populations, it can be inferred that the
immune system is often successful in detecting and destroying cancerous cells. Not only does
this fact suggest the importance of the immune system in the regulation of cancer, but it also
highlights an opportunity of cancer research that utilizes the patient’s immune system in fighting
malignant tumors.
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Figure 1. Characteristics of a Cancer Cell. From Hanahan, 2022.
Strategies employed by a malignant cell that allow the cell to become immortal, proliferate
continuously, and avoid destruction by the body. These characteristics are widely recognized as
the necessary for a cell to be deemed malignant, hence referencing these characteristics as
“hallmarks of a cancer cell.”
Conventional and Targeted Therapies
Treatment of cancer has evolved from blunt surgical removal to highly specific targeted
therapies since the 1970’s, narrowing the target of treatment from a macro to a micro scale.
Options for patients in the early twentieth century existed primarily in the realm of the surgeon
and later of radiation that eradicated cells with what could easily be described as a scorched
earth policy, destroying not only cancerous cells but any other cells within range (Chabner 2005).
Furthermore, these treatments could eliminate only relatively large tumors, leaving metastatic
cells and precancerous cells to continue to proliferate.
Clearly there was a need for new treatment options and throughout the later half of the
twentieth century chemotherapy options that are still used today were discovered. Among these
are Vinca alkaloids that inhibit microtubule polymerization and thus cell division, as well as a
broad combination of multiple known inhibitory mechanisms, known as the POMP regimen, in
1965. This regime was named from the drugs within the regime (6‐Mercaptopurine, Vincristine,
Methotrexate, Prednisone) that combined served as an attempt to treat a variety of cancer
subtypes (Bukowski 2020, Chabner 2005). The fact remained, however, that even with precise
treatments with drugs, the cytotoxicity and combination of several drugs severely impacted
organ function and blood cell regeneration (Chabner 2005). Furthermore, modern research has
shown that cancer cell resistance to these traditional drugs, termed multidrug resistance,
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achieved by the cancer cell through mutation and gene upregulation, complicates chemotherapy
drugs usage further, even when a combination of several drugs is used (Bukowski 2020).
This long‐standing issue, combined with a broadening knowledge of cell biology, led to
the discovery of targeted therapies in the late twentieth century and the subsequent expansion
of targeted therapy research to the scope it is today. A central underlying cause of the hallmark
of cancerous cells is the mutation of the genome which leads to the subsequent creation of
faulty proteins. The mutation of specific proteins provides a unique opportunity for highly
specified treatment, as a mutated protein can be treated with an inhibitor or an activator that
returns it to its original function thereby alleviating symptoms of cancer (Lee 2018). These
drugs, termed targeted therapies, work to reverse the previously discussed hallmarks of cancer
and therefore affect the same targets that cancer cells manipulate, such as cell surface antigens,
growth factors, and processes involved in the cell cycle (Lee 2018).
Broadly speaking targeted therapy drugs can be classified by what general aspect of
cancer physiology is affected, either the cancer cell itself or the manipulated tumor
microenvironment. Cancer cells by necessity must evade apoptosis through intrinsic and
extrinsic signals to become malignant, therefore targeted therapies often target effectors of
apoptosis to induce apoptosis in cancer cells and force them to be eliminated (Lee 2018).
Additionally, targeted therapies affect the tumor microenvironment to counteract molecules
released by tumor cells to promote tumor growth. One such example is anti‐angiogenesis drugs
that inhibit blood vessel growth and nutrient access to a growing tumor (Lee 2018).
A breakthrough in targeted therapy research came in the form of Gleevec, a treatment
that has since been used to great success in the treatment of chronic myeloid leukemia (CML)
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(Capdeville 2002). The identification of the gene BCR‐ABL in several forms of cancer and its
association with tyrosine kinase activity led to the suggestion of the mutated tyrosine kinase as
an excellent target for targeted therapy. This protein plays an important role in the proliferation
and survival of certain kinds of cancer cells where the BCR‐ABL gene is mutated to produce a
constitutively active tyrosine kinase. Gleeveceffectively targets this hyperactive protein and
antagonizes it, thus alleviating the symptoms and tumor growth associated with cancers such as
CML (Capdevile 2002). Gleevecpaved the way for other cancer targeted therapy drugs, all with
the same underlying mechanism of manipulating mutated pathways that drive cancer cell
survival and metastasis.
Cancer Cell Mechanisms of Apoptosis
As previously stated, cancer cells develop a wide array of mechanisms that allow for the
evasion of apoptosis, both from extrinsic and intrinsic factors. These factors often converge onto
specific pathways that end with the common characteristics of apoptosis such as cell membrane
blebbing and cell shrinkage. Caspases are a family of proteases that are essential to apoptosis
(Benetatos 2014, Dynek 2013). However, caspases often reside in the middle of pathways and
thus need to be activated and regulated by other molecules upstream and initially by receptor
activation.
One such molecule involved with cancer cell regulation of caspases are IAPs, or inhibitors
of apoptosis molecules, essential not only in apoptosis regulation but also in inflammation and
immunity (Benetatos 2014). Inhibitors of apoptosis endogenously inhibit apoptosis through the
sequestering and subsequent degradation and inactivation of caspases, thus halting the
apoptotic process (Fig. 2). In order to for a diseased cell to undergo apoptosis, IAPs need to be
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antagonized themselves (Vasudevan 2016). In a normal diseased cell, upon receiving an
apoptotic signal a secondary molecule called SMAC, secondary‐mitochondrial activator of
caspases, is released from the mitochondria and blocks the binding of IAPs to caspases, thereby
allowing caspases to continue the process of apoptosis.
However, the genes that encode for IAPs are known to mutate in cancer cells, making
the IAP product molecule highly susceptible to mutation. Mutated IAPs help a cancer cell
proliferate as well as remain alive after receiving an apoptotic signal through the inhibition of
caspases downstream of an extrinsic apoptotic signal (Dynek 2013). In cancerous cells, due to
the upregulation of IAPs, SMAC is no longer able to sequester IAPs away from the caspases and
apoptosis is halted. This inhibition is caused by two mechanisms, either direct caspases
antagonism or antagonism of SMAC to allow IAPs to bind to caspases. The direct binding of
caspases is completed by XIAPs whereas the sequestering of SMAC is done by cIAPs 1 and 2
(Dynek 2013). Cancer cells have been known to show upregulation of both XIAPs and cIAP 1/2,
therefore resulting in an immortal cell that no longer responses to apoptotic signaling (Dynek
2013).
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Figure 2. IAP Inhibition in Apoptotic Signal Transduction.
IAPs inhibit apoptosis by antagonizing SMAC, thus inactivating caspases.
SMAC Mimetics
SMAC’s endogenous inhibitory nature of IAPs presents it as a viable molecule to imitate
in the inhibition of IAPs. A study by Petrucci et al. on ovarian cancer cell line and
chemoresistance ovarian cancer cell line, observed a proapoptotic trend in cells treated with
SMAC mimetic largely due to the activation of a synergistic apoptotic pathway, tumor necrosis
factor‐related apoptosis relating ligand (TRAIL) (Petrucci 2007). Furthermore, Bockbrader et al.
similarly observed a pro‐apoptotic effect on breast cancer cells line, both utilizing SMAC
mimetics alone or in tandem with TRAIL inducing molecules (Bockbrader 2005). Both of these
studies suggest SMAC mimetics perform a pro‐apoptotic effect in cancer cell lines that evade
apoptosis through the upregulation of IAPs.
Further success has been shown in immune‐compromised mouse models implanted with
human tumors. When treated with SMAC mimetics that antagonize the dysfunctional IAPs
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sustained caspase activation and the completion of the apoptotic pathway was observed in
comparison to control subjects (Benetatos 2014). A study performed by Benetatos et. al.
suggests that SMAC mimetic Birinapant binds with high affinity to IAP molecules, thereby
allowing caspases downstream to be activated in a human breast cancer cell line model.
Furthermore, treatment with Birinapant increased cancer cell line sensitivity to traditional
chemotherapy drugs, giving treatment with Birinapant a two‐pronged effect (Benetatos 2014).
SMAC mimetics have gone beyond pre‐clinical trials however and have been the subject
of several clinical trials. A phase two clinical trial performed by Pemmaraju et al. tested SMAC
mimetic LCL161 with medium to high‐risk myelofibrosis patients. The results concluded that of
the fifty patients that received LCL161, several noticed a decrease in symptoms relating to
myelofibrosis, such as clinical improvement of anemia and transfusion independence
(Pemmaraju 2021). Although less drastic than the cell death observed in vitro with human cancer
cell lines, these results suggest that a deeper study into the effects of SMAC mimetics are
worthwhile in the treatment of cancer, either singularly or in tandem with traditional
chemotherapy options.
Immune System Overview
The protective nature of the immune system in regard to infectious disease has been well
known for centuries, the importance of this protection of the body against infectious diseases
can be witnessed best when immunity fails. Perhaps the most well‐known example of failure of
the immune system is HIV/AIDS patients and the extreme susceptibility to disease that
accompanies the HIV virus. After infection with HIV, a gradual destruction of immune cell
subtypes called memory and naïve CD4+ T cells eventually leads to the final stage of the disease,
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AIDS (Simon 2006). Susceptibility to diseases that a healthy immune system controls with
regularity is characteristic of a suppressed immune system, thereby exhibiting the importance
that the immune system has on day‐to‐day protection from infectious disease (Simon 2006).
The effects of the immune system are further exemplified by opportunistic infections
present in patients who have received aggressive therapies for cancer or other long‐term
illnesses, as well as in patients with transplant organs and therefore a chemically suppressed
immune system. These therapies often depress the immune system along with the desired effect
on the illness, thereby leaving the body unprotected against infections such as pneumonia and
cryptococcosis (L’Huillier 2020, Sepkowitz 2002). Moreover, genetically inherited primary
immunodeficiencies are characterized by an increased susceptibility to infections, depending on
what function of the immune system is genetically affected (Notarangelo 2009). In short,
immune‐suppressing conditions either created by immune suppressing drugs, infections, or
genetics indicate the importance of the immune system to the normal functioning of the body
and by extension prove that it is essential in the protection of not only foreign pathogens but
diseased cells as well.
Immune System and Cancer
The protection from cancer provided by the immune system has only recently begun to
be appreciated. As mentioned in previous sections, a hallmark of cancerous cells is the
development of mechanisms that allow cells to evade the attempts by the immune system to
eliminate defective cells such as cancerous cells. Both human and murine models with a
depressed immune system show a higher susceptibility to the development of cancer. RAG
knockout mice in particular have a higher likelihood of developing sarcomas when compared to
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wild‐type mice, therefore suggesting the importance of T and B cells on the detection of cancer
(Dunn 2004). Additionally, patients with suppressed immune systems due to HIV/AIDS or drugs
following organ transplants for example show increased likelihood of developing cervical cancer,
melanomas, Kaposi’s sarcoma, and Burkitt’s lymphoma in recent studies (Dugue 2013, Kubica
2012). In sum, these studies suggest the significance of the role of the immune system in the
detection and suppression of cancerous cells.
However, the proof that the immune system in some way affects the likelihood of the
development and subsequent progression of cancer is found beyond the cancer cells themselves
and in model systems of immune cell knockout models. RAG is an important gene in the
development of a certain type of immune cell critical to cancer detection. When RAG is
defective, mouse models lack several subpopulations of immune cells, including T cells, and B
cells (Dunn 2004). Additionally, patients born with SCID, severe combined immunodefiencies,
present with a severe lack of immune cells (immunodeficiency) as RAG defective mouse models
caused by genetic impairment of RAG genes (Sobacchi 2006).
Mechanisms and Counter Mechanisms of Cancer Immunity
Cancer immunity has developed several mechanisms to identified and destroy cancerous
cells, however cancer cells in turn have evolved counter mechanisms to remain unidentifiable
and immortal. The function of anti‐tumor T cells is essential in the management and destruction
of cancer cells and the understanding of the activation of T cells against cancerous cells, or
against any antigen in general, is vital to understanding tumor suppression. Within the immune
system two cells in particular play a prominent role in cancer defense. These cells are a type of
leukocyte (white blood cell) and are categorized into helper (CD4+) T cells and cytotoxic (CD8+) T
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cells. Helper T cells assist all other immune cells to become activated and function properly, a
role that is clearly vital to the function of the immune system as recognized in immune deficient
patients. Similarly, cytotoxic T cells are essential in the direct killing of infected or cancerous
cells. While CD4+ cells and CD8+ cells perform different roles within the anti‐tumor response but
are activated against cancerous cells through the same process. All T cells recognize antigen, or
a molecule that induces an immune response, through a membrane bound receptor called a
TCR, or T cell receptor. To bind to a TCR, an antigen must be presented within an MHC molecule
on an antigen‐expressing cell, an MHC class I for CD8+ T cells and MHC class II for CD4+ T cells.
Once the appropriate T cell binds to an MHC molecule, co‐stimulatory receptor called CD28 on
the T cells binds its ligand and provides the final signal needed to engage the T cells into
proliferation and activation.
Once produced in the thymus, a T cell enters the lymphatic system where it circulates
between lymph and the blood stream to search for its specific antigen and become activated.
This initial activation, or priming, occurs via dendritic cells (DCs) that process antigen and present
it on MHC molecules to activate T cells within lymph nodes. After this initial activation T cells
proliferate and exit into the blood stream to perform effector functions.
While the immune system is able to identify and destroy the vast majority of cancerous
cells, through utilizing evasion mechanisms some cancerous cells proliferate and metastasize. As
previously mentioned, cancer cells avoid destruction through evading detection by the immune
system altogether and instigating an immune‐repressive tumor microenvironment (TME)
(Gonzalez 2018). CD8+ cells are the most prominent of the anti‐tumor cells and destroy
cancerous cells through direct killing and are therefore crucial to the elimination of cancer
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(Gonzalez 2018). Along with CD8+ cells, the other subpopulation of T cells, CD4+ cells, secrete
pro‐inflammatory signal molecules, termed cytokines, to further activate CD8+ cells against
cancerous cells. Tumor cells are recognized for destruction by CD8+ cells through recognizing
antigens presented on the outside of cancerous cells, however tumor antigens presented by
cancer cells are notoriously poor for antigen presentation, further helping the cancer cell evade
detection (Sánchez‐Paulete 2017). This lack of expression occurs through mutation of genes
causing a downregulation of antigen expression. Those cells that have less expression are able to
survive and proliferate thus generating a tumor with cells that strictly do not express the
antigens needed for their destruction (Gonzalez 2018).
In addition to CD8+ cells, CD4+ cells provide helper functions to assist in the
accumulation of other immune cells to the tumor environment through the production of pro‐
inflammatory cytokines, making inflammation a hallmark of cancer. Cancer cells purposefully
generate a microenvironment that is hostile to immune cells. Mutated cells secrete immune‐
suppressive molecules, such as the previously mentioned IL‐10 and TGF‐B, thereby inhibiting
CD8+ cells and other immune cells from proliferating and functioning properly. In addition to the
secretion of suppressive cytokines, cancer cells express inhibitory molecules such as PD‐L1 that
actively bind to inhibitory receptors on T cells and halt proliferation of active anti‐tumor T cells
(Gonzalez 2018, Yaguchi 2011). These inhibitory molecules are vital in the survival of cancer cells,
and blockade of PD‐L1 and its receptor, PD‐1, have been shown to be effective treatments for
many types of cancers alongside chemotherapy (Yaguchi 2011).
Moreover, the inhibitory cytokines TGF‐B and IL‐10 in particular have more than one
immune‐suppressive effect within the tumor microenvironment. These molecules activate rather
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than inhibit regulatory T cells, a subpopulation of T cells that negatively regulate immune
responses to prevent excess inflammation. Furthermore, IL‐10 and TGF‐B activate regulatory
dendritic cells that further activate regulatory T cells, therefore generating a feedback loop
within the TME (Yaguchi 2011). By secreting cytokines that enhance regulatory T cell function,
cancer cells evade immune destruction through suppression of the anti‐tumor response and
activation of suppressive cells.
Another essential role of T cells is the generation of long‐lived memory T cells that are
able to recognize antigen and initiate an anti‐tumor response much quicker should cancerous
cells develop again (Waldman 2020). This is vital in long‐term suppression of cancer and the
betterment of the patient’s overall life. The overall goal of immunotherapy is to bolster this anti‐
tumor immune response against the mechanisms used by cancerous cells to suppress them and
utilize the immune system in the fight against tumors, but also to provide the immune system
the opportunity to generate cells for this long‐term response. Memory cells would not only
provide long‐term protection but also continue to provide a highly specified response that
destroys cancerous stem cells before they are able to generate tumors and metastasize.
IAPs and SMAC Mimetics
The bolstering of the immune system in the fight against cancer is possible through
several different means, but one option is SMAC mimetics. Beyond their ability to antagonize
IAPs, SMAC mimetics have also been shown to activate a specific pathway called the non‐
canonical NFkB pathway, in immune cells that, when activated, leads to the transcription of pro‐
inflammatory cytokines and the subsequent activation of immune cells. Endogenously, the non‐
canonical NF‐kB pathway is highly regulated through the processing of the p100 protein. This
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protein is tightly controlled and processed only through induction of the pathway, often through
members of the tumor neurosis family (TNF), a family of molecules essential to immune cell
function and activation.
Once a member of this family binds to its receptor on the surface of an immune cell, it
sends a signal to NIK (NF‐kB inducing kinase) whose predominant function is to mediate NF‐
kB activation and to in turn activate inhibitor of kB kinase (IKK). IKK will then cause p100 to
be ubiquitinated and broken down, allowing for transcription factors that cause the expression
of genes that lead to proinflammatory cytokines to enter the nucleus (Sun 2017, Zhu 2009).
Interestingly, this pathway can be inhibited by the same IAPs that inhibit apoptosis in cancer
cells, through binding to NIK and degrading it, thus halting the NF‐kB pathway before it can be
fully activated in immune cells (Fig. 3).
Through SMAC mimetics inhibiting IAPs the NF‐kB pathway is proposed to be activated.
This activation would bolster the immune system, alongside the traditional function of SMAC
mimetics, sensitizing cancer cells to apoptotic signals. Several studies have already demonstrated
the importance of expression of the NF‐kB pathway in immune cell function. Studies conducted
in 2010 by Dougan et al. found increased levels of proliferation and pro‐inflammatory cytokine
production in mouse immune cells in vivo when treated with increasing levels of SMAC mimetics.
Furthermore, human CD4+ T cells downregulated cIAPs when treated with mimetic. SMAC
mimetics were therefore suggested to not only increase activation in mouse T cells, specifically
CD4+ T cells, but also to downregulate cIAPs in human CD4+ T cells (Dougan 2010)
In addition, Knight et al. in 2013 observed the effect of SMAC mimetic LCL161 on
cytokine production specifically in human CD8+ and CD4+. Should SMAC mimetics antagonize
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IAPs and allow for activation of the non‐canonical NF‐kB pathway, cytokine production should be
increased in these populations of cells. Following in vitro stimulation, purified CD8+ and CD4+ T
cells showed an increase in production of pro‐inflammatory cytokine IL‐2 with increasing
concentrations of LCL161, further suggesting a possible activation of the NF‐kB pathway (Knight
2013). These studies suggest that SMAC mimetics might have two different anti‐
cancer mechanisms—a direct effect on cancer cell viability and an indirect effect via activating
anti‐tumor T cell responses. If true, this could have implications for combining SMAC mimetics
with immunotherapy.

Figure 3. Non‐canonical NF‐kB signaling.
A member of the TNF family binds to a receptor on the cell surface, activating NIK. NIK in turn
activates IKK, once activated IKK degrades p100 and allows for pro‐inflammatory transcription
factors to enter the nucleus. This transduction is inhibited by IAPs.
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Model System and Hypothesis
As observed by previous studies, treatment with SMAC mimetics have the ability to not only
initiate apoptosis in cancer cells that have upregulated IAPs, but also the hypothesized effect of
activating the non‐canonical NF‐kB pathway and subsequently increasing T cell activation and
proliferation (Dougan 2010, Knight 2013). Should these drugs activate the NF‐kB pathway
consistently, this would provide patients with a bolstered immune system alongside the primary
role of SMAC mimetics in targeting cancer cells. Study of these drugs and their effect on the
immune system are consequently of pertinent importance.
This study aimed to observe the direct effects of three clinically relevant SMAC mimetics ‐
Birinapant, LCL161, and BV6 ‐ on isolated human T cells and T cells in the context of other
circulating immune cells. Both populations of T cells were tested for increased proliferation and
cytokine levels using flow cytometry and ELISA to gauge the effect of SMAC mimetics on T cell
activation. The hypothesis of this study is as follows: SMAC mimetics will enhance T cell
proliferation and pro‐inflammatory cytokine production due to constitutive activation of the
non‐canonical NF‐kB pathway. The following discussion of methodology addresses how this
hypothesis was tested.

Materials and Methods
Human Subjects
Peripheral blood mononuclear cell (PBMC) samples were from donor de‐identified healthy
adult males obtained via leukapheresis. Subjects were aged 22‐56 and were seronegative for
HIV, CMV, and Hepatitis B. The present study was determined by the University of Portland
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Institutional Review Board to be exempt under category #4, as we have no access to or ability to
obtain identifying information about these donors.
Antibodies and flow cytometry
The following antibodies were used for flow cytometry analysis: CD8 (BD Biosciences, HIT8a),
CD4 (BD Biosciences, SK3), IFNg (Invitrogen, 4S.B3), CD3 (eBioscience, SK7), TNFα (eBioscience,
MAb11), IL‐2 (Invitrogen, MQ1‐17H12). The following antibodies were purchased
from BioLegend: CD25 (BC96), CD3 (SK7), Foxp3 (206D), TNFα (MAb11), CD8 (RPA‐T8), CD4
(OKT4). Stimulatory anti‐CD3 (OKT3) and anti‐CD28 (CD28.2) antibodies
were from BioLegend. Flow cytometry was performed on a FACSymphony or LSR II (BD
Biosciences). Data from flow cytometry was analyzed via FlowJo software (BD Biosciences).
Media and other reagents
T cells were cultured in RPMI 1640 (Life Technologies) supplemented with 2 mM L‐Glutamine
(Life Technologies), 100 U/ml Penicillin (Invitrogen), 100 ug/ml Streptomycin
(Invitrogen) and 10% FBS (R&D Systems). MDA‐MB‐231 breast cancer cells were grown in
DMEM (Life Technologies) supplemented as above. FACS buffer consisted of 1x PBS, 2% FBS
and 0.1% NaN3. Cell proliferation dye labeling buffer consisted of 1x PBS/0.1% (w/v) BSA (Sigma
Aldrich). IAP antagonists (SMAC mimetics) Birinapant, BV6, and LCL161 were from MedChem
Express and Apex Bio, and were reconstituted at 10mM in DMSO and stored at –80° C.
T Cell Culture
T cells were isolated from PBMCs with EasySep™ Human T cell Isolation Kit per manufacturer’s
instructions (StemCell Technologies). Cells were isolated via labeling with magnetic antibodies to
remove all cells with the exclusion of T cells. Cells were then washed and decanted, separating T
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cells from other white blood cell populations. Isolated T cells (0.5‐1 x 105 per well) or
unseparated PBMCs (1 x 105 per well) were stimulated for 48‐72 hours either with Dynabeads™
Human T Activator CD3/CD28 antibody coated beads (Thermo Fisher) at 2:1 or
4:1 bead:cells ratios or with plate‐bound anti‐CD3 and soluble anti‐CD28, each at 2 ug/ml in the
presence of varying concentrations of IAP antagonists. Cells were incubated at 37°C and 6.0%
CO2.
In some experiments, cells were labeled with CFSE or Cell Trace e450 proliferation dye
(Thermofisher) prior to culture. CFSE proliferation dye was used to track cell division through the
incorporation of dye prior to growth, dilution of dye was observed as cells divided. Cells were
incubated with 10uM CFSE or CTe450 in 1x PBS/0.1%BSA for 15 minutes at 37°C, then washed
three times before culture.
Intracellular Cytokine Staining (ICCS) and Flow Cytometry
For proliferation measurements, cells were first stained with Zombie aqua fixable viability dye
(Biolegend) for 15 minutes to label live/dead cells, then surface antibodies for 20 min, then
washed and fixed in 1% paraformaldehyde before flow cytometric analysis. For apoptosis
assessment of PBMC and T cells, following surface staining, cells were stained with Annexin
V (R&D Systems) per manufacturer’s instructions and were run immediately without fixation or
were fixed in 1% PFA diluted in Annexin V binding buffer, containing CaCl2 to preserve Annexin V
binding. To measure intracellular cytokines, cells were treated with GolgiPlug™ (BD BioScience)
for the last 5 hours of culture, then stained with fixable viability dye and surface antibodies as
above. GolgiPlug™ was used to stop secretion of cytokines intracellularly to allow for cytokine
measurement. Cells were then permeabilized using Invitrogen eBioscience™ intracellular staining
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kit per manufacturer’s protocol and stained for IFNg, TNFa and IL‐2. Cells were run on a BD LSR
II or BD Symphony and analyzed using FlowJo (BD Biosciences).
Apoptosis of MDA‐MB‐231 cells
MDA‐MB‐231 breast cancer cells were a kind gift from Dr. Pepper Schedin, OHSU. To assess
apoptosis induced by IAP antagonists on these IAP overexpressing cells, MDA‐MB‐231 cells were
cultured at in the presence of the indicated concentrations of IAP antagonist for 48 hours. Cells
were assessed for apoptosis with Annexin V staining kit (R&D Systems) per manufacturer’s
instructions and were analyzed immediately via flow cytometry.
Secreted Cytokines
IL‐2 and IFNg were assessed in cell culture supernatants via commercial ELISA. ELISAs were
performed by the sequential additions of capture antibody, supernatant sample, detection
antibody and finally fluorescent detection conjugate with washes in between each addition. IL‐2
Human Uncoated ELISA kit and IFNg Human Uncoated ELISA kit (both from
Invitrogen) and DuoSet Human IFN‐gamma kit and Ancillary Reagent Kit 2 (R&D Systems) were
performed according to manufacturer’s instructions. ELISA plates were read on iMark™
Microplate Reader (BioRad) and data analyzed with Excel.
Western Blot
2 x 106 T cells isolated from PBMC were stimulated with plate‐bound anti‐CD3 alone or anti‐
CD3 plus anti‐CD28 for 24 or 48 hours. Cells were lysed in RIPA buffer and protein extracts from
equal numbers of cells were resolved on a 12% SDS‐PAGE gel (Biorad), followed by transfer
onto Immun‐Blot PVDF membranes (Biorad). Membranes were blocked in 5% non‐fat dry milk
and probed overnight with rabbit anti‐NF‐kB2 p100/p52 and GAPDH
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antibodies at 1:1000, followed by washing and 2 hour incubation with goat‐anti‐rabbit‐HRP
antibody at 1:5000 (all from Cell Signaling Technology). Membranes were washed again and
detected with SuperSignal West Pico Chemiluminescent substrate (Thermofisher). Protein
band intensities were quantified with ImageJ (NIH).

25

Figures

26

27

28

29

Results
SMAC Mimetics are able to activate the NF‐kB pathway in human immune cells at concentrations
that kill tumor cells.
SMAC mimetics have been shown to antagonize IAPs which can activate the non‐
canonical NF‐kB pathway through the inhibition of cIAPs 1/2 (Dougan et al. 2010, Giardino
Torchia et al. 2013, Jin et al. 2009). To test the activation of NF‐kB in human T cells, cells were
treated with Birinapant and assessed via Western blot for the presence of p100/p52 isoforms.
Increasing concentrations of Birinapant activated non‐canonical NF‐kB in primary human T cells,
as assessed by increased processing of NF‐kB2 from the p100 to p52 isoform (figure 1A). In
addition, birinapant exhibited no toxicity to T cells in doses up to at least 1uM (figure 1B). In
clinical trials, Birinapant exhibited a tissue concentration of around 0.8 uM in patients (Noonan
et al. 2016). In contrast, SMAC mimetics in this study induced apoptosis of the sensitive breast
cancer cell line DA‐MB231 at >100‐fold lower doses (figure 1C).
SMAC mimetics have negligible effects on T cell proliferation
Given that non‐canonical NF‐kB activation is intrinsically important for T cell clonal
expansion (Murray 2011), the effect of SMAC mimetics was tested on T cell proliferation. In
purified T cells, increasing dosage of all three SMAC mimetics resulted in negligible change in
proliferation observed in normalized percent of cells divided (figure 2B). Within these
populations of dividing cells, no trend is shown in CD25 MFI, further suggesting that SMAC
mimetics have little to no effect on isolated T cells proliferation (figure 2B). Since non‐canonical
NF‐kB activation has also been shown to affect antigen presenting cells, SMAC mimetics
affecting T cells proliferation indirectly was considered. Thus, the effect of SMAC mimetics on T
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cell proliferation in the context of total PBMC cultures was tested. However, even in the
presence of accessory cells, SMAC mimetics did not affect T cell proliferation (figure 2C) or CD25
expression (supplementary figure 1).
Addition of SMAC mimetic Birinapant does not increase secreted pro‐inflammatory cytokine
production in T cells
Previous studies showed that SMAC mimetics can increase pro‐inflammatory
cytokines IFNg and IL‐2 (Dougan et al 2010, Knight et al. 2013). To test secreted cytokine
production, supernatant from separated T cells and T cells within PBMC cultures
was assessed for IL‐2 and IFNg by ELISA. Both IL‐2 and IFNg production showed no increase in
the presence of Birinapant in either cell population (figure 3A). Likewise, cytokines were not
increased in the presence of BV6 or LCL‐161 (supplementary figure 2). Data from all five subjects
were normalized to each subjects’ cytokine production at 0 uM and no trend is evident
throughout all five subjects’ normalized data (figure 3B).
Birinapant does not affect intracellular pro‐inflammatory cytokine production
It was possible that SMAC mimetics altered cytokine production on a per cell basis, but
that these changes were obscured by subsequent consumption of the cytokines produced.
To directly assess cytokine production in individual CD4 and CD8 T cells, ICCS was performed on
magnetically separated T cells as well as T cells within PBMCs. Once again, no trend in either
CD4+ T cell populations nor CD8+ T cells populations (figure 4B) is shown with increasing dosage
for IL‐2+ or IFNg+ cells, and there is a trend for SMAC mimetics to actually decrease double
producers of TNFa+/IFNg+ (figure 4A). Clearly addition of SMAC mimetics has negligible effect
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on increase in cytokine production both in secreted cytokines as well as in intracellular
cytokines.

Discussion
This study sought to answer the question of what effect SMAC mimetics have on the
proliferation and activation of human T cells. The previously stated hypothesis suggested that
SMAC mimetics would enhance T cell proliferation and pro‐inflammatory cytokine production
due to constitutive activation of the non‐canonical NF‐kB pathway. Then data collected indicate
that none of the drugs tested improved T cell responses in any of the numerous culture
conditions and measures we analyzed. Before testing on culture samples, SMAC mimetics were
assessed for viability in killing a cancer cell line, toxicity towards human immune cells, and ability
to activate the non‐canonical NF‐kB pathway. In line with previous studies, SMAC
mimetics showed viability in killing tumor cells while also remaining non‐toxic to immune cells
within physiologic concentration. The concentrations used throughout the study were well
within range of a non‐toxic dose, eliminating the possible theory of cell death due to addition of
any of the SMAC mimetics. Furthermore, analysis by Western blot shows Birinapant’s ability to
activate the NF‐kB pathway with evident cleavage of the p100 isoform to the p52 in line with
previous studies performed by Dougan et al (Dougan 2010).
T cell proliferation due to the addition of SMAC mimetics had been suggest in previous
studies however the results of the present study show little to no proliferation in separated T
cells or T cells within PBMC culture. In contrast to previous results, these data resulted from
testing with multiple drugs across a range of concentration with several different outputs of
proliferation analyzed. Costimulation with both Dynabeads as well as plate bound aCD28 and

32

aCD3 were used as well. Cytokine secretion was also found to be different in this study
compared to previous studies done by Knight et al that suggested an increase in IL‐2 production.
However, our data suggest no trend in increasing cytokine production, including IL‐2 but
extending to IFNg, IL‐2 and TNFa. These cytokines could potentially be secreted and then
consumed, but no increase in either secreted cytokine nor intracellular cytokine makes this
unlikely. In sum, the same conclusions made in studies done with a single mimetic cannot be
assumed with cells exposed to multiple mimetics under multiple different conditions as was seen
in our data.
The data from this study suggest either that the NF‐kB pathway is not activated by
exposure to SMAC mimetics, as previous studies have suggested (Dougan 2010, Knight 2013), or
that the NF‐kB pathway is activated but provides no benefit to immune cells at the level of
activation achieved. Clear cleavage of p100 to p52 upon treatment of T cells with Birinapant was
observed. However, this “boost” that is thought to be given to immune cells through the
activation of NF‐kB could simply be low enough that it produces no noticeable increase in T cell
activation or proliferation. Alternately, non‐canonical NF‐kB activation may exert opposing pro
and anti‐activation effects on human T cells. That non‐canonical NF‐kB activation may play a
lesser role in human versus mouse T cells is supported by the phenotype of patients with biallelic
loss of function mutations in NIK, a central kinase in the non‐canonical NF‐kB pathway
(Willmann et al. 2014). These patients had severe B cell defects, but no alterations in T cell
subsets or in T cell proliferation in response to anti‐CD3 or mitogen stimulation. Although they
had reduced T cell recall responses to TT and PPD antigens, this was likely the result of poor T
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cell priming in the absence of lymph nodes in these patients. Finally, SMAC mimetics may have
off‐target effects in T cells that counteract the effects of activating non‐canonical NF‐kB.
The present study suggests the proposed dual mechanistic ability of SMAC mimetics to
be untrue. Clinically this would limit the mechanism of action of SMAC mimetics to solely
targeted therapy as these results further shed doubt on these drugs’ ability to synergize with
checkpoint blockade or other forms of immunotherapy. Nevertheless, the data found in this
study uncovered the evidently narrow window in which any response to T cell proliferation is
due to addition of SMAC mimetics. The difficulty to reach this narrow window in vitro makes the
ability to generate an appropriate response in vivo all that more challenging.
Traditional methods of chemotherapy, including therapy and broad‐spectrum drugs,
target all rapidly dividing cells thus making them blunt instruments in the fight against cancer.
While targeted therapy drugs act on specific targets in comparison to traditional drugs, pathways
in which these molecules are found are rarely specific. A molecule within a pathway utilized by
cancer, such as IAPs, may be involved in the functioning of several other cell types, making the
targeting of this molecule dangerous in any context outside of a cancer cell. In future research of
targeted therapies it will be important to recognize that, as shown above, targeted therapies
effect more than one cell type, specifically of systems like the immune system that are beneficial
in the fight against cancer.

34

Acknowledgements
I would like to acknowledge and give my utmost thanks to Dr. Susan Murray for her
constant guidance and support throughout the duration of this project.
Furthermore, I would like to thank my lab partner and project partner Brittney
Ligman for her support and efforts towards making this project a success. Thank
you both for all of your help. I would also like to thank the University of Portland
Department of Biology for financially supporting this work and the Murdock
Charitable Trust for their financial support as well. Lastly, I would like to thank the
Hill Lab at OHSU and the Knight Cancer Research Institute for their contributions to
this project.

35

Works Cited
Benetatos, C. A., Mitsuuchi, Y., Burns, J. M., Neiman, E. M., Condon, S. M., Yu, G., ... & Chunduru,
S. K. (2014). Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2‐associated
cIAPs, abrogates TNF‐induced NF‐κB activation, and is active in patient‐derived xenograft
models. Molecular cancer therapeutics, 13(4), 867‐879.
Bockbrader, Mingjia Tan, & Yi Sun. (2005). A small molecule Smac‐mimic compound induces
apoptosis and sensitizes TRAIL‐ and etoposide‐induced apoptosis in breast cancer
cells. Oncogene, 24(49), 7381–7388. https://doi.org/10.1038/sj.onc.1208888
Bukowski, K., Kciuk, M., & Kontek, R. (2020). Mechanisms of multidrug resistance in cancer
chemotherapy. International journal of molecular sciences, 21(9), 3233.
Capdeville, Buchdunger, E., Zimmermann, J., & Matter, A. (2002). Gleevec(STI571, imatinib), a
rationally developed, targeted anticancer drug. Nature Reviews. Drug Discovery, 1(7),
493–502. https://doi.org/10.1038/nrd839
Chabner, B. A., & Roberts, T. G. (2005). Chemotherapy and the war on cancer. Nature Reviews
Cancer, 5(1), 65‐72.
Chen, & Huerta, S. (2009). Smac mimetics as new cancer therapeutics. Anti‐Cancer Drugs, 20(8),
646–658. https://doi.org/10.1097/CAD.0b013e32832ced78
Dougan, M., Dougan, S., Slisz, J., Firestone, B., Vanneman, M., Draganov, D., ... & Dranoff, G.
(2010). IAP inhibitors enhance co‐stimulation to promote tumor immunity. Journal of
Experimental Medicine, 207(10), 2195‐2206.
Dugue, P. A., Rebolj, M., Garred, P., & Lynge, E. (2013). Immunosuppression and risk of cervical
cancer. Expert review of anticancer therapy, 13(1), 29‐42.
Dunn, Old, L. J., & Schreiber, R. D. (2004). The three Es of cancer immunoediting. Annual Review
of Immunology, 22(1), 329–360.
https://doi.org/10.1146/annurev.immunol.22.012703.104803

36

Dynek, J. N., & Vucic, D. (2013). Antagonists of IAP proteins as cancer therapeutics. Cancer
letters, 332(2), 206‐214.
Gonzalez, H., Hagerling, C., & Werb, Z. (2018). Roles of the immune
system in cancer: from tumor initiation to metastatic
progression. Genes & development, 32(19‐20), 1267‐1284.
Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. cell, 100(1), 57‐70.
Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12(1), 31‐46.
Kubica, A. W., & Brewer, J. D. (2012, October). Melanoma in immunosuppressed patients.
In Mayo Clinic Proceedings (Vol. 87, No. 10, pp. 991‐1003). Elsevier.
Knights, A. J., Fucikova, J., Pasam, A., Koernig, S., & Cebon, J. (2013). Inhibitor of apoptosis
protein (IAP) antagonists demonstrate divergent immunomodulatory properties in
human immune subsets with implications for combination therapy. Cancer Immunology,
Immunotherapy, 62(2), 321‐335.
Lee, Tan, Y. J., & Oon, C. E. (2018). Molecular targeted therapy: Treating cancer with specificity.
European Journal of Pharmacology, 834, 188–196.
https://doi.org/10.1016/j.ejphar.2018.07.034
L'Huillier, Ferreira, V. H., Hirzel, C., Nellimarla, S., Ku, T., Natori, Y., Humar, A., & Kumar, D.
(2020). T‐cell responses following Natural Influenza Infection or Vaccination in Solid
Organ Transplant Recipients. Scientific Reports, 10(1), 10104–10104.
https://doi.org/10.1038/s41598‐020‐67172‐6
Pemmaraju, N., Carter, B. Z., Bose, P., Jain, N., Kadia, T. M., Garcia‐Manero, G., ... & Verstovsek,
S. (2021). Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for
patients with myelofibrosis. Blood Advances, 5(16), 3163‐3173.
Petrucci, E., Pasquini, L., Petronelli, A., Saulle, E., Mariani, G., Riccioni, R., Biffoni, M., Ferretti, G.,
Benedetti‐Panici, P., Cognetti, F., Scambia, G., Humphreys, R., Peschle, C., & Testa, U.
(2007). A small molecule Smac mimic potentiates TRAIL‐mediated cell death of ovarian
cancer cells. Gynecologic oncology, 105(2), 481–492.
https://doi.org/10.1016/j.ygyno.2007.01.011

37

Sánchez‐Paulete, Teijeira, A., Cueto, F. ., Garasa, S., Pérez‐Gracia, J. ., Sánchez‐Arráez, A., Sancho,
D., & Melero, I. (2017). Antigen cross‐presentation and T‐cell cross‐priming in cancer
immunology and immunotherapy. Annals of Oncology, 28, xii74.
https://doi.org/10.1093/annonc/mdx727
Sepkowitz, K. A. (2002). Opportunistic infections in patients with and patients without acquired
immunodeficiency syndrome. Clinical infectious diseases, 34(8), 1098‐1107.
Simon, V., Ho, D. D., & Karim, Q. A. (2006). HIV/AIDS epidemiology, pathogenesis, prevention,
and treatment. The Lancet, 368(9534), 489‐504.
Sun, S. C. (2017). The non‐canonical NF‐κB pathway in immunity and inflammation. Nature
Reviews Immunology, 17(9), 545‐558.
Vasudevan, D., Ryoo, H. D. (2015). Regulation of Cell Death by IAPs and Their
Antagonists. Current topics in developmental biology, 114, 185–208.
https://doi.org/10.1016/bs.ctdb.2015.07.026
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020). A guide to
cancer immunotherapy: from T cell basic science to clinical
practice. Nature Reviews Immunology, 20(11), 651‐668.
Yaguchi, T., Sumimoto, H., Kudo‐Saito, C., Tsukamoto, N., Ueda, R., Iwata‐Kajihara, T., ... &
Kawakami, Y. (2011). The mechanisms of cancer immunoescape and development of
overcoming strategies. International journal of hematology, 93(3), 294‐300.
Zhu, M., & Fu, Y. (2010). The complicated role of NF‐κB in T‐cell selection. Cellular & molecular
immunology, 7(2), 89‐93.

38

